Pyxis Oncology, Inc. (NASDAQ: PYXS) announced it will host a live webcast on September 9, 2026, at 7:30 am Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study. The study evaluates micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Clinical Presentation Details

The presentation will cover the scientific rationale for MICVO, a novel antibody-drug conjugate (ADC), and its implications within the evolving treatment landscape for R/M HNSCC. Key data points include detailed analyses of patients treated at 5.4 mg/kg intravenously once every three weeks, specifically those receiving a dose equivalent to or below a dose cap.

Updated efficacy and safety results from the expansion trial will be disclosed, alongside next steps in clinical development. The event features Alan L. Ho, M.D., Ph.D., Chief of Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center, along with Pyxis Oncology management.

Regulatory and Development Context

MICVO holds Fast Track Designation from the U.S. Food and Drug Administration for treating adult patients with R/M HNSCC whose disease progressed following platinum-based chemotherapy and anti-PD-(L)1 therapy. The drug targets extradomain-B of fibronectin (EDB+FN), a structural component of the tumor extracellular matrix selectively overexpressed in solid tumors.

Pyxis Oncology is also evaluating MICVO in combination with Merck’s KEYTRUDA (pembrolizumab) in a Phase 1/2 study for R/M HNSCC and other solid tumors. An archived webcast will be available on the company’s investor relations website following the live event.

Pyxis Oncology Inc (NASDAQ: PYXS) has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026. The leadership change coincides with the company’s push to advance clinical milestones for its lead candidate, MICVO.

Civik, who served as Interim Chief Executive Officer since February 2026 and joined the board in 2021, brings extensive experience from previous roles at ImCheck Therapeutics, Repare Therapeutics, Five Prime Therapeutics, Foundation Medicine, and Genentech.

Leadership Transition

John Flavin, co-founder and founding Chairman, will transition to the role of Lead Independent Director. Flavin will continue to serve on the board, providing oversight during this strategic phase. The board cited Civik’s demonstrated leadership and disciplined execution during his interim tenure as key factors in the appointment.

Civik expressed gratitude for Flavin’s vision and guidance since the company’s inception. He emphasized the team’s focus on generating clinical evidence for MICVO to address unmet needs in head and neck cancer treatment.

Clinical Pipeline Updates

Pyxis Oncology expects to report updated data from two key studies in 2026:

• Phase 1 monotherapy study of MICVO in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the fall of 2026. This update will include analysis of patients treated at or below dose cap, covering safety, tolerability, efficacy, and initial durability.
• Phase 1/2 combination study of MICVO with pembrolizumab in first-line R/M HNSCC in the fourth quarter of 2026.

MICVO holds Fast Track Designation from the U.S. Food and Drug Administration for treating adult patients with R/M HNSCC whose disease progressed following platinum-based chemotherapy and anti-PD-(L)1 therapy.

What the Numbers Show

The appointment of a permanent CEO after seven months of interim leadership signals a stabilization of executive management ahead of critical clinical readouts. Civik’s background in commercializing oncology therapies, including roles at companies acquired by major pharmaceutical firms like Amgen and Ipsen, aligns with Pyxis Oncology’s need to navigate complex regulatory and clinical pathways for its antibody-drug conjugate candidate.